TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT: 75M)(OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce that it has entered into a non-binding term sheet to form a strategic joint venture with San Martino S.S. (“San Martino”), a large scale agricultural company in the Piedmont Region of Italy, founded by Milan businessman Umberto Signorini. Pursuant to the proposed joint venture Maricann and San Martino will develop a centre of excellence for cannabis products, in conjunction with the University of Eastern Piedmont, initially producing high CBD content for the medical market, and then ultimately THC product for the European market. The formation of the joint venture remains subject to due diligence and the negotiation and execution of definitive documentation.



Federico Riboldi, Vice President, Province of Alessandria stated, “It is a true pleasure to see the start of the collaboration of Maricann with San Martino to develop a CBD and THC project here in Italy, specifically, Alessandria province. I think we have found the best combination of people to become the first CBD and THC company in Italy."

Umberto Signorini Jr. commented, “The partnership between Maricann and the Signorini Family to develop CBD products is very exciting. There are great opportunities for the cosmetic, alimentary, veterinary, pharmaceutical, and recreational sectors."

"We're proud to partner with San Martino and the Signorini family and have received unprecedented governmental support for the initiative. Our first mover advantage in cannabis from Canada has proffered the opportunity to work with established and respected groups in Europe, and now in Italy with San Martino. We will bring our world leading technology, developed in conjunction with Rockwell Automation to automate and standardize cannabis production and subsequent products, while gaining advantage from existing infrastructure in Piemonte, including biogas electricity produced from San Martino's facilities," stated Ben Ward, CEO of Maricann.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Such statements include statements regarding the formation and business of the proposed joint venture. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations

Graham Farrell

Director of Investor Relations

graham@maricann.com

647-643-7665



Corporate Headquarters (Canada)

Maricann Group Inc. (Toronto)

845 Harrington Court, Unit 3

Burlington Ontario L7N 3P3

Canada

289-288-6274



European Headquarters (Germany)

Maricann GmbH

Thierschstrasse 3, 80538 Munchen, Deutschland